{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:51:49Z","timestamp":1790077909541,"version":"4.0.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011760","name":"CARE","doi-asserted-by":"publisher","award":["115620"],"award-info":[{"award-number":["115620"]}],"id":[{"id":"10.13039\/501100011760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"European Union Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"FP7","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.cmi.2018.11.025","type":"journal-article","created":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T02:36:31Z","timestamp":1544409391000},"page":"515.e1-515.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacodynamic modelling of \u03b2-lactam\/\u03b2-lactamase inhibitor checkerboard data: illustration with aztreonam\u2013avibactam"],"prefix":"10.1016","volume":"25","author":[{"given":"A.","family":"Chauzy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Buyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.L.M.","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Couet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2018.11.025_bib1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1469-0691.2012.03821.x","article-title":"Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe","volume":"18","author":"Canton","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.11.025_bib2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1517\/14656566.2016.1145658","article-title":"Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply \u201cprecision medicine\u201d to antimicrobial chemotherapy?","volume":"17","author":"Perez","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cmi.2018.11.025_bib3","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1128\/AAC.00206-15","article-title":"In\u00a0vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013","volume":"59","author":"Biedenbach","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2018.11.025_bib4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2018.11.025_bib5","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1128\/AAC.40.8.1914","article-title":"Comparison of three different in\u00a0vitro methods of detecting synergy: time-kill, checkerboard, and E test","volume":"40","author":"White","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2018.11.025_bib6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijantimicag.2007.10.025","article-title":"Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities","volume":"31","author":"Martins","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2018.11.025_bib7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.micres.2014.02.009","article-title":"Treatment of infectious disease: beyond antibiotics","volume":"169","author":"Nigam","year":"2014","journal-title":"Microbiol Res"},{"key":"10.1016\/j.cmi.2018.11.025_bib8","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/cc11441","article-title":"Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics","volume":"16","author":"Schulz","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2018.11.025_bib9","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1128\/AAC.06113-11","article-title":"Novel modeling framework to guide design of optimal dosing strategies for beta-lactamase inhibitors","volume":"56","author":"Bhagunde","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2018.11.025_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/jac\/48.6.813","article-title":"A\u00a0pharmacokinetic\/pharmacodynamic approach to show that not all fluoroquinolones exhibit similar sensitivity toward the proconvulsant effect of biphenyl acetic acid in rats","volume":"48","author":"Marchand","year":"2001","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2018.11.025_bib11","first-page":"1","article-title":"EUCAST Discussion Document E. Dis 5.1: determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution","volume":"9","author":"European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID)","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.11.025_bib12","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1128\/AAC.04146-14","article-title":"In\u00a0vitro activity of ceftazidime-avibactam combination in in\u00a0vitro checkerboard assays","volume":"59","author":"Berkhout","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2018.11.025_bib13","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2018.11.025_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/psp4.12159","article-title":"Prediction of in\u00a0vivo and in\u00a0vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms","volume":"6","author":"Sy","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18307729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18307729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:22:25Z","timestamp":1761117745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X18307729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1198743X18307729"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2018.11.025","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic modelling of \u03b2-lactam\/\u03b2-lactamase inhibitor checkerboard data: illustration with aztreonam\u2013avibactam","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2018.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}